Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Tuberculosis re-treatment after exclusion of rifampicin resistance

Chen-Yuan Chiang, Arnaud Trébucq
European Respiratory Journal 2018 51: 1702282; DOI: 10.1183/13993003.02282-2017
Chen-Yuan Chiang
1International Union Against Tuberculosis and Lung Disease, Paris, France
2Division of Pulmonary Medicine, Dept of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
3Division of Pulmonary Medicine, Dept of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cychiang@theunion.org
Arnaud Trébucq
1International Union Against Tuberculosis and Lung Disease, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Once rifampicin resistance is excluded, it might be wiser to use the category II regimen in TB retreatment http://ow.ly/KLJE30hDX0I

To the Editor:

We agree with Falzon et al. [1] that treatment of isoniazid-resistant tuberculosis (TB) is an important issue. The first-line re-treatment regimen for previously treated TB patients, which was known as the category II regimen, comprised 8 months of isoniazid, rifampicin and ethambutol supplemented by streptomycin for the initial 2 months, and pyrazinamide for the initial 3 months (2SHRZE/HRZE/5HRE). It was introduced in the collaborative programme of the International Union Against Tuberculosis and Lung Disease in which the first-line initial regimen for new TB patients was an 8-month regimen comprising 2 months of isoniazid, rifampicin, pyrazinamide and streptomycin, followed by 6 months of isoniazid and thioacetazone (2HRZS/6HT) [2]. At that time, the prevalence of multidrug-resistant (MDR)-TB among previously treated TB cases was relatively low and the challenge was mainly isoniazid resistance [3]. The category II regimen was designed to overcome isoniazid resistance and to reduce the risk of acquired resistance to rifampicin. It performed fairly well in settings where resistance to isoniazid predominated among previously treated TB patients [4]. However, with the wide use of a 6-month regimen including rifampicin throughout the whole treatment course (2HRZE/4HR) for new TB patients (category I regimen), the prevalence of rifampicin resistance among previously treated TB patients increased substantially [5], rendering the category II regimen ineffective and problematic.

In 2017, World Health Organization (WHO) recommended that in “patients who require TB retreatment, the category II regimen should no longer be prescribed and drug-susceptibility testing should be conducted to inform the choice of treatment regimen” [6]. It is indeed crucial to perform rapid drug susceptibility testing to detect rifampicin resistance. After the exclusion of rifampicin resistance, the issue of isoniazid resistance remains and the challenge of patients with isoniazid resistance without rifampicin resistance cannot be neglected [7].

While recommending not using the category II regimen, the Guideline Development Group expressed concern regarding treatment of patients with isoniazid-resistant TB and advised that “Providers must be vigilant about the possibility of isoniazid resistance and, if it is suspected, they must test for isoniazid susceptibility and treat accordingly” [6]. Unfortunately, the most widely available rapid drug-susceptibility testing (DST) is Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA), which detects resistance to rifampicin but not isoniazid. Line probe assays can detect isoniazid resistance but are not easily accessible. A small fraction of re-treatment TB patients may have conventional DST but it is not uncommon to have a long turnaround time in high TB burden countries. A newly developed cartridge using the GeneXpert platform for the rapid molecular detection of resistance to fluoroquinolones, aminoglycosides and isoniazid has very high sensitivity and specificity in the detection of isoniazid resistance but is not yet widely available [8].

This raises an important question: what regimen should be used in re-treatment TB after rifampicin resistance has been excluded by the Xpert test? The WHO guidelines indicated that “on the basis of the drug susceptibility profile, a standard first-line treatment regimen (2HRZE/4HR) can be repeated if no resistance is documented” [6]; however, it did not provide clear guidance on regimens to be used when the DST of isoniazid is lacking. It is highly likely that the category I regimen will be used in TB retreatment (personal communication from the national TB programme of the Philippines and Viet Nam). The problem is that the category I regimen may not necessarily be better than the category II regimen in TB re-treatment, especially in patients with isoniazid-resistant TB.

Meta-analysis shows that the pooled event rates of failure, relapse and acquired resistance in previously treated patients with isoniazid resistance who were treated with the category II regimen were all lower than those in new TB patients with isoniazid resistance who were treated with the category I regimen: ­­6% versus 11% for failure, 5% versus 10% for relapse and 3% versus 8% for acquired drug resistance (table 1) [9]. Furthermore, the proportion of acquired resistance that is MDR-TB was 71% (95% CI 29–96%) in the former group and 98% (95% CI 92–99%) in the latter group. This provided indirect evidence that by using effective drugs together with rifampicin for a longer period, the category II regimen may outperform the category I regimen in TB re-treatment, especially in protecting rifampicin, which is in line with the findings of another network meta-analysis [10]. This is not surprising because the category II regimen was initially designed to address isoniazid resistance in TB retreatment.

View this table:
  • View inline
  • View popup
TABLE 1

Failure, relapse and acquired drug resistance in new tuberculosis patients with isoniazid resistance without rifampicin resistance treated with the World Health Organization (WHO) new# regimen and in previously treated tuberculosis patients treated with the WHO re-treatment¶ regimen

Using a 6-month category I regimen in TB re-treatment after rifampicin resistance being excluded may run a higher risk of acquired resistance to rifampicin than using the category II regimen in settings where isoniazid monoresistance is substantial and obtaining results of DST of isoniazid in a timely manner is not feasible. It might be wiser not to abandon the category II regimen prematurely before a better option is available in TB re-treatment.

Footnotes

  • Conflict of interest: None declared.

  • Received November 3, 2017.
  • Accepted December 4, 2017.
  • Copyright ©ERS 2018

References

  1. ↵
    1. Falzon D,
    2. Schünemann HJ,
    3. Harausz E, et al.
    World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49: 1602308.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Enarson DA
    . Principles of IUATLD Collaborative Tuberculosis Programmes. Bull Int Union Tuberc Lung Dis 1991; 66: 195–200.
    OpenUrlPubMed
  3. ↵
    1. Trébucq A,
    2. Anagonou S,
    3. Gninafon M, et al.
    Prevalence of primary and acquired resistance of Mycobacterium tuberculosis to antituberculosis drugs in Benin after 12 years of short-course chemotherapy. Int J Tuberc Lung Dis 1999; 3: 466–470.
    OpenUrlPubMed
  4. ↵
    1. Gninafon M,
    2. Tawo L,
    3. Kassa L, et al.
    Outcome of tuberculosis retreatment in routine conditions in Cotonou, Benin. Int J Tuberc Lung Dis 2004; 8: 1242–1247.
    OpenUrlPubMedWeb of Science
  5. ↵
    1. Zignol M,
    2. van Gemert W,
    3. Falzon D, et al.
    Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012; 90: 111–119.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. World Health Organization
    . Guidelines for treatment of drug-susceptible tuberculosis and patient care. 2017 update. World Health Organization Document 2017: WHO/HTM/TB/2017.05. Geneva, WHO, 2017.
  7. ↵
    1. Stagg HR,
    2. Lipman MC,
    3. McHugh TD, et al.
    Isoniazid-resistant tuberculosis: a cause of concern? Int J Tuberc Lung Dis 2017; 21: 129–139.
    OpenUrl
  8. ↵
    1. Xie YL,
    2. Chakravorty S,
    3. Armstrong DT, et al.
    Evaluation of a rapid molecular drug-susceptibility test for tuberculosis. N Engl J Med 2017; 377: 1043–1054.
    OpenUrl
  9. ↵
    1. Gegia M,
    2. Winters N,
    3. Benedetti A, et al.
    Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis 2017; 17: 223–234.
    OpenUrlCrossRef
  10. ↵
    1. Stagg HR,
    2. Harris RJ,
    3. Hatherell HA, et al.
    What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis. Thorax 2016; 71: 940–949.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 51 Issue 2 Table of Contents
European Respiratory Journal: 51 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Tuberculosis re-treatment after exclusion of rifampicin resistance
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Tuberculosis re-treatment after exclusion of rifampicin resistance
Chen-Yuan Chiang, Arnaud Trébucq
European Respiratory Journal Feb 2018, 51 (2) 1702282; DOI: 10.1183/13993003.02282-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Tuberculosis re-treatment after exclusion of rifampicin resistance
Chen-Yuan Chiang, Arnaud Trébucq
European Respiratory Journal Feb 2018, 51 (2) 1702282; DOI: 10.1183/13993003.02282-2017
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Rifapentine access in Europe: concerns over key TB treatment
  • P. aeruginosa membrane vesicles cause endothelial barrier failure
  • Mortality after admission with pneumonia higher than after admission with COPD exacerbation
Show more Agora

Correspondence

  • Extracorporeal life support as a bridge to lung transplantation strategy in anti-MDA5+ rapidly progressive interstitial lung disease is life-saving but with persistent difficulties at the bedside
  • Liver cancer in severe alpha-1 antitrypsin deficiency: Who is at risk?
  • Cancer risk in severe alpha-1-antitrypsin deficiency - the importance of the early identification
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society